title: Is heart failure a debatable end-point for bisphosphonate treatment in older osteoporotic population?
authors.affiliation: Türkiye Yüksek İhtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey.
authors.forename: U
authors.initials: U
authors.lastname: Canpolat
authors.forename: A
authors.initials: A
authors.lastname: Gökçay Canpolat
authors.forename: D
authors.initials: D
authors.lastname: Aras
authors.forename: S
authors.initials: S
authors.lastname: Aydoğdu
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D008297:Male
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates